CAMBRIDGE, Mass.--(BUSINESS WIRE)--Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that preclinical data related to CUDC-305, the company’s Heat Shock Protein (HSP) 90 inhibitor, was published online this week in Molecular Cancer Therapeutics. The paper also will be published in the print version of this journal shortly. The paper is authored by Rudi Bao, M.D., Ph.D. et al and is entitled “Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer.” The data discussed in this paper were generated prior to Curis’ entry into a license agreement in August 2009 with Debiopharm Group, which has since renamed the compound Debio 0932.
